Tag: funding

TORONTO, June 25, 2025 /CNW/ - Canadians eager to support local now have a new way to discover and buy home–grown products. BuyCanadianGroup.ca is...

Every year in B.C., approximately 130 children are diagnosed with cancer. As the province's only full-service acute-care hospital dedicated to children, BC Children's Hospital...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TSXV: FWZOTCQX: FWEDFFSE: M0G VANCOUVER, BC, June 25, 2025 /CNW/ - FIREWEED METALS...

Hamilton, Bermuda, June 25, 2025 – Golar LNG Limited (the “Company”) (NASDAQ: GLNG) announces today that it intends to offer, subject to market and other conditions, $500 million aggregate principal amount of Convertible Senior Notes due 2030 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also intends to grant the initial purchasers of the Notes a 30-day option to purchase up to an additional $75 million aggregate principal amount of the Notes in connection with the offering.

DAN: TSX-V (Canada)JE9N: FSE (Germany)DRRSF: OTCQX (USA) SAGUENAY, QC, June 25, 2025 /CNW/ - Arianne Phosphate (the "Company" or "Arianne") (TSXV: DAN) (OTCQX: DRRSF) (FRANKFURT: JE9N),...

Grants advance research and pilot programs to prevent musculoskeletal disorders WASHINGTON, June 25, 2025 /PRNewswire/ -- The National Safety Council awarded $300,000 to the 2025-2026 Research...

The 1.3-mile Westside Trail–Segment 4 project connects communities from Pittsburgh Yards to Blandtown, delivering 6.7 miles of uninterrupted pathway alongside historic Washington Park ATLANTA, June...

PUNE, India, June 25, 2025 /PRNewswire/ -- Credence Research, a leading market research and consulting firm has released its most recent research about the...

PUNE, India, June 25, 2025 /PRNewswire/ -- Credence Research, a leading market research and consulting firm has released its most recent research about the...

Guidesly Guides now have a New AI Tool with the Invention of Guidesly's Jack AI™Jack AI Provides the Guidesly Guide a No-Touch, AI Experience...

SKYX Provides Corporate Update

New strategic partnership will accelerate the scale-up of high-impact immunization delivery innovations BRUSSELS, June 25, 2025 /CNW/ - Grand Challenges Canada (GCC), one of the world's...

Bipartisan majorities favor higher not lower taxes on the wealthy, cutting defense spending not increasing it, no cuts to Medicaid, reducing deficit not increasing...

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a genetic disorder caused by a chromosome 22 deletion, presenting symptoms like heart defects, immune deficiencies, and developmental delays. Market growth is driven by advancements in diagnostic technologies like next-generation sequencing (NGS) and chromosomal microarray analysis (CMA), enabling early detection and tailored interventions. Despite the lack of a cure, targeted therapies, such as Zynerba Pharmaceuticals' Zygel, are emerging. Increased awareness, research funding, and strategic collaborations are enhancing patient care and shaping a promising future for the 22q11.2 deletion syndrome market.

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a genetic disorder caused by a chromosome 22 deletion, presenting symptoms like heart defects, immune deficiencies, and developmental delays. Market growth is driven by advancements in diagnostic technologies like next-generation sequencing (NGS) and chromosomal microarray analysis (CMA), enabling early detection and tailored interventions. Despite the lack of a cure, targeted therapies, such as Zynerba Pharmaceuticals' Zygel, are emerging. Increased awareness, research funding, and strategic collaborations are enhancing patient care and shaping a promising future for the 22q11.2 deletion syndrome market.